Jill Buck

Jill serves as EVP, GM Gene Therapy at Ziopharm. She has over 20 years of clinical research experience overseeing Phase 1-IV clinical programs in drugs, devices and biologics. Prior to joining Ziopharm, Jill was Group Vice President of Global Clinical Operations at Synageva Biopharm Corp, where she oversaw the teams responsible for the clinical trials resulting in US, EU and Japanese approvals of sebelipase alfa for LAL Deficiency. Prior to Synageva, Jill held roles of increasing responsibility in Clinical Operations at Ziopharm, Averion International, Control Delivery Systems and The TIMI Study Group at Brigham and Women’s Hospital. Jill holds a bachelor’s degree in English and Communications from Boston College.